A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)

An Open-Label, Phase 1 Study to Characterize the Effects of Belzutifan on the Pharmacokinetics of a MATE1/2K Substrate, Metformin, in Healthy Adult Participants

The goal of this study is to learn how belzutifan (MK-6482) affects the levels of metformin in a healthy person's body over time. Researchers will study levels of metformin in the blood and urine in healthy volunteers after taking metformin alone (Period 1) and metformin with belzutifan (Period 2).

The main inclusion criteria include, but are not limited to:

• Is a continuous non-smoker for at least 3 months prior to dosing
• Has body mass index (BMI) ≥ 18.0 and ≤ 42.0 kg/m2
• Is able to swallow multiple tablets

The main exclusion criteria include, but are not limited to:

• Has a history of cancer (malignancy)
• Has a history of anemia within the last 5 years
• Has a known history or presence of metabolic acidosis, ketoacidosis, or lactic acidosis
• Has a hemoglobin level below the lower limit of normal
• Has a pulse oximetry reading less than 92% at rest
• Is known to be a cytochrome P450 (CYP2C19) poor metabolizer or likely poor metabolizer based on genotyping prior to the screening visit or is determined to be a CYP2C19 poor metabolizer